Currently out of the existing stock ratings of Brian Abrahams, 268 are a HOLD (39.88%), 399 are a BUY (59.38%), 5 are a SELL (0.74%).

Brian Abrahams

Work Performance Price Targets & Ratings Chart

Analyst Brian Abrahams, currently employed at RBC, carries an average stock price target met ratio of 44.22% that have a potential upside of 31.4% achieved within 216 days.

Brian Abrahams’s has documented 1,305 price targets and ratings displayed on 41 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on GILD, Gilead Sciences at 11-Dec-2024.

Wall Street Analyst Brian Abrahams

Analyst best performing recommendations are on CNST (CONSTELLATION PHARMACEUTICALS).
The best stock recommendation documented was for CNST (CONSTELLATION PHARMACEUTICALS) at 10/10/2019. The price target of $20 was fulfilled within 27 days with a profit of $11.9 (146.91%) receiving and performance score of 54.41.

Average potential price target upside

of $84.51 (9.66%) on REGN (REGENERON PHARMACEUTICALS).
of $45.77 (53.32%) on SRPT (SAREPTA THERAPEUTICS).
of $41.64 (25.67%) on KRTX (KARUNA THERAPEUTICS).

ATAI ATAI Life Sciences BV BIIB Biogen CELG Celgene DVAX Dynavax Technologies ENTA Enanta Pharmaceuticals ETN Eaton PLC GILD Gilead Sciences GLPG Galapagos NV ADR HOOK Hookipa Pharma ICPT Intercept Pharmaceuticals INCY yte ITCI Intracellular Th KPTI Karyopharm Therapeutics KRTX Karuna Therapeutics MRUS Merus BV NBIX Neurocrine Biosciences OVID Ovid Therapeutics PLRX Pliant Therapeutics PTCT PTC Therapeutics SAGE Sage Therapeutic SRPT Sarepta Therapeutics VRTX Vertex Pharmaceuticals CNST Constellation Pharmaceuticals IGMS IGM Biosciences BCRX BioCryst Pharmaceuticals ALDR Alder BioPharmaceuticals MRNS Marinus Pharmaceuticals MTCR Metacrine XENE Xenon Pharmaceuticals ETNB 89bio PRTA Prothena plc REGN Regeneron Pharmaceuticals NBSE NeuBase Therapeutics ACHN Achillion Pharmaceuticals CRBP Corbus Pharmaceuticals EIGR Eiger Biopharmaceuticals ITMN InterMune MNMD Mind Medicine MRTX Mirati Ther PTI Proteostasis Therapeutics AMAM Ambrx Biopharma . American Depositary Shares

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Sumant Kulkarni (CANACCORD)